Consensus Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 18/09/2026 am IST			5-day change	1st Jan Change
49.02 ^USD	-0.71%		-10.25%	+11.28%

16/09	Scholar Rock Shares Fall After Barclays Downgrade	MT
16/09	Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says	MT

Evolution of the Average Target: Scholar Rock Holding Corporation

Evolution of the Target Price: Scholar Rock Holding Corporation

Changes in Analyst Recommendations: Scholar Rock Holding Corporation

a0d32c782a1846f69c19.U8npAKvPTHmy4Fc8IGC5kJIktdC9Atj4q-zuihMadtU.J73eMMb_PxbWlw5EYTiI4tp7xYPtTIGs7bik23xqQbsdvIZa8YE8S9ePEg~4809bca3520f07f8eaac7a0ce0df3c9a

Analysts' recommendations: Scholar Rock Holding Corporation

16/09	Scholar Rock Shares Fall After Barclays Downgrade	MT
15/09	Barclays Downgrades Scholar Rock to Equalweight From Overweight, Adjusts PT to $58 From $55	MT
14/09	Wedbush Adjusts Price Target on Scholar Rock to $70 From $64, Keeps Outperform Rating	MT
14/09	Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating	MT
21/08	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT
21/04	Canaccord Genuity Initiates Scholar Rock at Buy With $62 Price Target	MT
31/03	Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating	MT
04/03	Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating	MT
03/03	Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating	MT
07/01	UBS Initiates Scholar Rock Holding at Buy With $60 Price Target	MT
14/11	Wedbush Adjusts Pt on Scholar Rock Holding to $50 From $43, Maintains Outperform Rating	MT
23/25/23	HC Wainwright Adjusts Price Target on Scholar Rock Holding to $44 From $50, Maintains Buy Rating	MT
23/25/23	Scholar Rock's Apitegromab Approval Still Likely Despite Delay, Wedbush Says	MT
17/25/17	Barclays Initiates Scholar Rock at Overweight With $45 Price Target	MT
15/25/15	Leerink Partners Initiates Scholar Rock at Outperform With $51 Price Target	MT
06/25/06	Biopharma Scholar Rock Q2 net loss widens, no revenue	RE
18/25/18	Truist Raises Price Target on Scholar Rock Holding to $54 From $45, Keeps Buy Rating	MT
17/25/17	Cantor Fitzgerald Initiates Coverage on Scholar Rock With Overweight Rating	MT
27/25/27	Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating	MT
25/24/25	Wedbush Raises Price Target on Scholar Rock to $47 From $40, Maintains Outperform Rating	MT
25/24/25	Truist Securities Adjusts Price Target on Scholar Rock to $45 From $36, Maintains Buy Rating	MT
12/24/12	Wedbush Raises Price Target on Scholar Rock to $40 From $37, Maintains Outperform Rating	MT
08/24/08	Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says	MT
07/24/07	Scholar Rock's Phase 3 Apitegromab Trial in Spinal Muscular Atrophy Meets Primary Endpoint	MT
07/24/07	Wedbush Raises Price Target on Scholar Rock Holding to $27 From $25, Keeps Outperform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SCHOLAR ROCK HOLDING CORPORATION					+41.66%
	WUXI APPTEC CO., LTD.					+18.61%
	ARGENX SE					+20.4%
	INSMED INCORPORATED					+62.79%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.41%
	BIONTECH SE					+23.92%
	GENMAB A/S					+10.98%
	PHARMAESSENTIA CORPORATION					+15.96%
	EXELIXIS, INC.					-5.45%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+34.53%
	Average					+23.98%
	Weighted average by Cap.					+22.89%